论文部分内容阅读
难治与复发白血病的治疗是当前临床上颇为棘手的难题,大剂量化疗或造血干细胞移植的疗效都不理想,开发新的化学药物以及组成新的化疗方案是寻求突破这一难题的重要举措之一。近年国外一些研究中心开展了含有拓扑替康、氟达拉滨及吉西他滨的化疗方案治疗难治与复发白血病的临床试验。本文在简要介绍这三种新型化疗药物的作用机制及药代动力学的基础上,重点对其治疗难治与复发白血病的疗效作一评估。
The treatment of refractory and relapsed leukemia is a very difficult clinical problem at present, and the effects of high-dose chemotherapy or hematopoietic stem cell transplantation are not satisfactory. Developing new chemical drugs and forming new chemotherapy programs are important measures to seek breakthrough in this problem one. In recent years, some foreign research centers to carry out topotecan, fludarabine and gemcitabine chemotherapy regimen in the treatment of refractory and relapsed leukemia clinical trials. Based on the brief introduction of the mechanism and pharmacokinetics of these three novel chemotherapeutic drugs, this review focuses on the evaluation of their therapeutic efficacy in refractory and relapsed leukemia.